Chris Ryan
Managing Editor at OncLive
Managing Editor at MJH Life Sciences
Managing Editor, @OncLive. Noted tall person. Recovering sports reporter. Past: @njdotcom. I know way too much about the Devils.
Articles
-
1 day ago |
onclive.com | Chris Ryan
The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) harboring high c-MET protein overexpression who have received a prior systemic therapy.
-
1 day ago |
onclive.com | Chris Ryan
The FDA has approved belzutifan (Welireg) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. The regulatory decision was supported by findings from the phase 2 LITESPARK-015 trial (NCT04924075), which showed that patients achieved an overall response rate (ORR) of 26% (95% CI, 17%-38%). The median duration of response (DOR) was 20.4 months (95% CI, 8.3-not reached).
-
1 day ago |
onclive.com | Chris Ryan
Generic, AB-rated formulations of eltrombopag (Promacta) as an oral suspension and a tablet are now commercially available for the treatment of select patients with severe aplastic anemia and immune thrombocytopenia.1,2 Specifically, the generic oral suspension and tablet formulations of eltrombopag are approved in the following indications: For patients with severe aplastic anemia who are insufficiently responsive to immunosuppressive therapy For patients 1 year of age and older with...
-
2 days ago |
onclive.com | Chris Ryan
Switzerland has granted marketing authorization to piflufolastat (18F) [Pylclari; formerly (18F)-DCFPyL] for the detection of prostate-specific membrane antigen (PSMA)–positive lesions with PET in select adult patients with prostate cancer.1 Specifically, the imaging agent is indicated for primary staging in patients with high-risk prostate cancer prior to initial curative therapy; and to localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum...
-
2 days ago |
oncnursingnews.com | Chris Ryan
The nectin-4–targeted antibody-drug conjugate (ADC) ADRX-0706 has received FDA fast track designation for use in patients with locally advanced or metastatic squamous cell cervical cancer.1The agent is currently being investigated in patients with select advanced solid tumors—including cervical cancer—in a phase 1 trial (NCT06036121). Interim data from the complete dose-escalation portion of the study will be presented at the 2025 ASCO Annual Meeting.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 11K
- Tweets
- 26K
- DMs Open
- Yes
the night the Devils won the draft lottery in 2017, I talked to Ray Shero later that night "How's it going, Ray?" "Just terrible, Chris." he also once talked for 45 minutes answering one question. what a gem. RIP
Glorias, ranked: 1-Gloria (Laura Branigan version) 2-Gloria (Estefan) 3-Gloria (church version)
the Avalanche now have the same goalie tandem as the 2016-17 Albany Devils
